Background. Mesenchymal stem cells (MSC) are progenitors of mesenchymal tissues such
as bone, cartilage, and adipose. Adult human leukocyte antigen (HLA)-matched MSC have …

Osteogenesis imperfecta (OI) can be recognized prenatally with ultrasound. Transplantation
of mesenchymal stem cells (MSCs) has the potential to ameliorate skeletal damage. We …

The inherited skeletal dysplasia osteogenesis imperfecta (OI) results in multiple fractures
and is currently treated empirically. We transplanted human first-trimester fetal blood …

Treatment with isolated allogeneic mesenchymal cells has the potential to enhance the
therapeutic effects of conventional bone marrow transplantation in patients with genetic …

Transplantation of whole bone marrow (BMT) as well as ex vivo–expanded mesenchymal
stromal cells (MSCs) leads to striking clinical benefits in children with osteogenesis …

Preclinical models have shown that transplantation of marrow mesenchymal cells has the
potential to correct inherited disorders of bone, cartilage, and muscle. The report describes …

Osteogenesis imperfecta (OI or brittle bone disease) is a disorder of connective tissues
caused by mutations in the collagen genes. We previously showed that intrauterine …

Prenatal transplantation of stem cells is an exciting frontier for the treatment of many
congenital diseases. The fetus may be an ideal recipient for stem cells, as it is …

In principle, transplantation of mesenchymal progenitor cells would attenuate or possibly
correct genetic disorders of bone, cartilage and muscle, but clinical support for this concept …

Abstract Purpose of Review Osteogenesis imperfecta (OI) is a chronic disease with few
treatment options available. The purpose of this review is to provide an overview on treating …